Neuromodulation for treatment-resistant depression
نویسندگان
چکیده
منابع مشابه
Neuromodulation for treatment-resistant depression
Treatment-resistant depression affects at least 1-3% of the US population. This article reviews the current state of focal neuromodulation therapies for treatment-resistant depression, focusing on those treatments published clinical data. These include transcranial magnetic stimulation, transcranial direct current stimulation, magnetic seizure therapy, vagus nerve stimulation, direct cortical s...
متن کاملCORRIGENDUM TO: Neuromodulation for treatment-resistant depression
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes.
متن کاملUpdate on Neuromodulation for Treatment-Resistant Depression
About 30% of patients suffering from a major depressive disorder do not respond sufficiently to established pharmacological, psychotherapeutic, or somatic treatments. Advances in technology and emerging knowledge about the dysfunctional brain circuits underlying depression have led to the development of different neuromodulation techniques. The aim of the present review is to give an update on ...
متن کاملNeuromodulation therapies and treatment-resistant depression
BACKGROUND Patients with treatment-resistant depression (TRD) who showed partial response to pharmacological and psychotherapeutic interventions need a trial of neuromodulation therapies (NTs). OBJECTIVE This paper aims to review evidence-based data on the use of NTs in TRD. METHOD Using keywords and combined-word strategy, multiple computer searches of PubMed, Google Scholar, Quertle(R), a...
متن کاملModeling treatment-resistant depression.
Depression is a polygenic and highly complex psychiatric disorder that is currently a major burden on society. Depression is highly heterogeneous in presentation and frequently exhibits high comorbidity with other psychiatric and somatic disorders. Commonly used treatments, such as selective serotonin reuptake inhibitors (SSRIs), are not ideal since only a subset of patients achieve remission. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: F1000 Medicine Reports
سال: 2012
ISSN: 1757-5931
DOI: 10.3410/m4-22